Mutsuhiro Ikuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mutsuhiro Ikuma has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Takahisa Furuta
Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
23 shared publications Chise Kodaira
18 shared publicationsMasafumi Nishino
17 shared publicationsMihoko Yamade
17 shared publications- Mitsushige Sugimoto
Center for Clinical Research, Hamamatsu University School of Medicine, Japan
16 shared publications Akira Hishida
12 shared publications
Latest Publications
- Open Access
- 8 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 544-553
Concordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug Applications in Japan
New drug applications (NDAs) in Japan are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA). Those that pass the review are subsequently subject to deliberation by the Ministry of Health, Labour and Welfare Pharmaceutical Affairs and Food Sanitation Councils (MHLW‐PAFSC), and the MHLW legislatively grants approval based on its positive opinions. However, little is known regarding the relationship between the PMDA review and the MHLW decision. We retrospectively assessed the MHLW decision of NDAs that passed the PMDA review at the initial MHLW‐PAFSC deliberation from 2002 to 2022. The reasoning behind a non‐supportive opinion from the MHLW‐PAFSC and the sponsor's actions to overcome unresolved issues were also documented. A total of 2,117 of 2,153 (98.3%) NDAs that passed the PMDA review were approved at the initial MHLW‐PAFSC deliberation with a positive opinion. The remaining 36 applications were not approved at the initial deliberation and subjected to continued deliberation because of a non‐supportive opinion from the councils, although 29 were finally approved through revision of the application document (24 applications), re‐analysis of the data (1 application), or additional clinical trials (4 applications). Seven applications have not been approved, of which one was refused, four were withdrawn, and two were unknown. The MHLW approves NDAs that passed the PMDA review at the initial deliberation at a high rate, suggesting that NDAs only suitable for approval passed the review and reached the MHLW‐PAFSC deliberation. Only a few NDAs were not approved at the initial deliberation; however, most of them were finally approved.
- 8 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 544-553
Open AccessConcordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug Applications in Japan
New drug applications (NDAs) in Japan are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA). Those that pass the review are subsequently subject to deliberation by the Ministry of Health, Labour and Welfare Pharmaceutical Affairs and Food Sanitation Councils (MHLW‐PAFSC), and the MHLW legislatively grants approval based on its positive opinions. However, little is known regarding the relationship between the PMDA review and the MHLW decision. We retrospectively assessed the MHLW decision of NDAs that passed the PMDA review at the initial MHLW‐PAFSC deliberation from 2002 to 2022. The reasoning behind a non‐supportive opinion from the MHLW‐PAFSC and the sponsor's actions to overcome unresolved issues were also documented. A total of 2,117 of 2,153 (98.3%) NDAs that passed the PMDA review were approved at the initial MHLW‐PAFSC deliberation with a positive opinion. The remaining 36 applications were not approved at the initial deliberation and subjected to continued deliberation because of a non‐supportive opinion from the councils, although 29 were finally approved through revision of the application document (24 applications), re‐analysis of the data (1 application), or additional clinical trials (4 applications). Seven applications have not been approved, of which one was refused, four were withdrawn, and two were unknown. The MHLW approves NDAs that passed the PMDA review at the initial deliberation at a high rate, suggesting that NDAs only suitable for approval passed the review and reached the MHLW‐PAFSC deliberation. Only a few NDAs were not approved at the initial deliberation; however, most of them were finally approved.
- 1 June 2011
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 4 (3) , 151-156
Successful treatment of ulcerative colitis complicated by Sweet’s syndrome by corticosteroid therapy and leukocytapheresis
Ulcerative colitis is occasionally complicated by dermatological disorders presenting as extra-intestinal manifestations, including erythema nodosum and pyoderma gangrenosum. Sweet’s syndrome is considered to be a rare cutaneous disease in patients with ulcerative colitis. To date, only 17 cases of Sweet’s syndrome complicating ulcerative colitis have been reported in the English literature. Here, we report a case of a 41-year-old male who had been suffering from ulcerative colitis for 20 years. He was admitted to hospital with hematochezia, diarrhea and fever, and painful erythematous nodules on the face and arms. Histological examination of skin biopsies showed inflammatory cell infiltration composed mainly of neutrophils without evidence of necrotizing vasculitis, and the condition was diagnosed as Sweet’s syndrome. The patient was treated with prednisolone and leukocytapheresis and the erythematous nodules on the skin, as well as the abdominal symptoms and endoscopic findings of ulcerative colitis, immediately improved. In this paper we report on this case and review the literature concerning ulcerative colitis and Sweet’s syndrome.
- 1 June 2011
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 4 (3) , 151-156
Successful treatment of ulcerative colitis complicated by Sweet’s syndrome by corticosteroid therapy and leukocytapheresis
Ulcerative colitis is occasionally complicated by dermatological disorders presenting as extra-intestinal manifestations, including erythema nodosum and pyoderma gangrenosum. Sweet’s syndrome is considered to be a rare cutaneous disease in patients with ulcerative colitis. To date, only 17 cases of Sweet’s syndrome complicating ulcerative colitis have been reported in the English literature. Here, we report a case of a 41-year-old male who had been suffering from ulcerative colitis for 20 years. He was admitted to hospital with hematochezia, diarrhea and fever, and painful erythematous nodules on the face and arms. Histological examination of skin biopsies showed inflammatory cell infiltration composed mainly of neutrophils without evidence of necrotizing vasculitis, and the condition was diagnosed as Sweet’s syndrome. The patient was treated with prednisolone and leukocytapheresis and the erythematous nodules on the skin, as well as the abdominal symptoms and endoscopic findings of ulcerative colitis, immediately improved. In this paper we report on this case and review the literature concerning ulcerative colitis and Sweet’s syndrome.
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Development of a Tailored Prophylaxis Strategy for Naproxen-Induced Gastric Injury Based on the 13C-Naproxen Breath Test
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Development of a Tailored Prophylaxis Strategy for Naproxen-Induced Gastric Injury Based on the 13C-Naproxen Breath Test
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Alteration in Fecal COX-2 mRNA Expressions Before and After Surgical or Endoscopic Resection of Colorectal Cancer and Adenoma
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Alteration in Fecal COX-2 mRNA Expressions Before and After Surgical or Endoscopic Resection of Colorectal Cancer and Adenoma
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Treatment Options for Non-Erosive Gastroesophageal Reflux Disease Patients Refractory to Frequent Dose Rabeprazole Therapy
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Treatment Options for Non-Erosive Gastroesophageal Reflux Disease Patients Refractory to Frequent Dose Rabeprazole Therapy
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Norepinephrine Suppresses the TH1-Type Cytokines Production of Murine Intestinal Intraepithelial Lymphocytes via β1-Adrenoreceptor
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Norepinephrine Suppresses the TH1-Type Cytokines Production of Murine Intestinal Intraepithelial Lymphocytes via β1-Adrenoreceptor
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Efficacy of Genetics-Based Regimens for Eradicating of Helicobacter pylori Infections
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Efficacy of Genetics-Based Regimens for Eradicating of Helicobacter pylori Infections
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Expression of Dicer mRNA and Alteration of 3'Untranslated Regions in Colorectal Cancer
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Expression of Dicer mRNA and Alteration of 3'Untranslated Regions in Colorectal Cancer
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Fecal Beta2-Microglobulin and Creatine Kinase B mRNA Assays as a Marker for Colorectal Cancer Screening
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Fecal Beta2-Microglobulin and Creatine Kinase B mRNA Assays as a Marker for Colorectal Cancer Screening